Clinical Trials on Squamous Cell Head and Neck Carcinoma in Korea, Democratic People's Republic of

Total 1044 results

Novartis Pharmaceuticals

Terminated

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1)

Non-Small Cell Lung Cancer

United States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada, Turkey, China, New Zealand, Hungary, Poland, Australia, Japan, Israel, Bel... and more
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, Colorectal

United States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Pfizer

Completed

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Kidney Neoplasms

Korea, Republic of, United States, Canada, Spain, Italy, United Kingdom, China, Singapore, Slovakia, France, Japan, Australia, Germany, Taiwan, Brazil, Russian Federation, India, Poland, Austria, Greece, Ireland, Sweden
Hoffmann-La Roche
Exelixis

Active, not recruiting

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)

Carcinoma, Non-Small-Cell Lung

United States, France, Belgium, United Kingdom, Australia, Korea, Republic of, Austria, Italy, Portugal, Spain, Poland, Japan, Germany, Greece, Russian Federation
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Non-Small Cell Lung Cancer

Poland, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukr... and more
Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, China, Korea, Republic of, Belgium, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Non-Small Cell Lung Cancer

Poland, United States, Brazil, France, Guatemala, Hungary, Japan, Korea, Republic of, Peru, Romania, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Daiichi Sankyo
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

Small Cell Lung Cancer

United States, Spain, Germany, Hungary, China, Italy, Korea, Republic of, United Kingdom, France, Belgium, Japan, Taiwan, Netherlands, Australia, Portugal, Poland, Turkey, Switzerland, Brazil, Canada, Romania
AbbVie

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, Australia, France, Belgium, China, Austria, United Kingdom, Germany, South Africa, Mexi... and more
GlaxoSmithKline

Active, not recruiting

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)

Lung Cancer, Non-Small Cell

Argentina, Korea, Republic of, Spain, Finland, Taiwan, Italy, Netherlands, Germany, Australia, Mexico, United States, Belgium, Canada, United Kingdom, Greece, Romania, Sweden, Russian Federation, Poland, France, Brazil, Japan, Thailand and more
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Renal Cell Carcinoma

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, United Kingdom
Pfizer

Active, not recruiting

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Renal Cell Cancer

United States, Hungary, Spain, United Kingdom, Belgium, Korea, Republic of, Canada, Israel, Denmark, Australia, Italy, Japan, France, Austria, New Zealand, Romania, Russian Federation, Netherlands, Germany, Mexico, Sweden
United Therapeutics

Completed

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Spain, Australia, Korea, Republic of, France, United Kingdom, Thailand, Malaysia, Hungary, Poland, Taiwan, Philippines, Hong Kong, Lithuania, Georgia, Bulgaria, India, Italy, Romania, Russian Federation, Slo... and more
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
Hoffmann-La Roche

Terminated

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Renal Cell Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Argentina, Australia, Belgium, Brazil, China, Denmark, Ireland, Spain, Japan, Netherlands, Chile, Czechia, Italy, France, Israel, Turkey, Germany, Austria, Taiwan, Serbia, Poland, Thailan... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Metastatic Non Small Cell Lung Cancer

Denmark, United States, Argentina, Australia, Austria, Belgium, Brazil, Finland, France, Germany, Israel, Italy, Korea, Republic of, Malaysia, Poland, Russian Federation, Spain, Switzerland, Taiwan, Thailand
AstraZeneca

Active, not recruiting

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

Non-Small Cell Lung Cancer

Belgium, Italy, Spain, United States, Poland, India, Taiwan, Thailand, Vietnam, Canada, France, Germany, Korea, Republic of, Brazil, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation, China, Austria, Chile, Netherlands, Bulg... and more
GlaxoSmithKline

Active, not recruiting

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (ZEAL-1L)

Lung Cancer, Non-Small Cell

Argentina, France, Spain, Italy, Belgium, Korea, Republic of, United States, Mexico, Hungary, Sweden, Turkey, Ireland, Greece, Russian Federation, Germany, Netherlands, Bulgaria, Romania, Brazil, United Kingdom, Poland, Australia, C... and more
Eli Lilly and Company

Completed

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

United States, China, Italy, Australia, Spain, Germany, Belgium, United Kingdom, Hungary, Taiwan, Austria, France, Poland, Greece, Netherlands, Brazil, India, Romania, Turkey, Russian Federation, Argentina, South Africa, Korea, Republic... and more
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Australia, France, Hong Kong, Italy, Portugal, Spain, United Kingdom, Brazil, Poland, Guatemala, Singapore, Thailand, Serbia, Ukraine, Bosnia and Herzegovina, China, Costa Rica, E... and more
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Adenocarcinoma

United States, Japan, Puerto Rico, Taiwan, Spain, Australia, France, Israel, Korea, Republic of, Poland
Bristol-Myers Squibb

Completed

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Small Cell Lung Carcinoma

Germany, Korea, Republic of, Poland, Taiwan, United States, China, Hong Kong, Spain, Australia, Italy, Russian Federation, Mexico, France, Japan, Switzerland, Austria, Belgium, Canada, Czechia, Hungary, Ireland, Israel, Netherlands, Peru and more
Takeda

Active, not recruiting

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)

ALK+ Advanced NSCLC

Spain, China, Korea, Republic of, Taiwan, Hong Kong, Thailand, Italy, Romania, United States, Mexico, Croatia, Russian Federation, Argentina, Canada, Germany, France, Austria, Chile, Greece, Sweden
Hoffmann-La Roche

Active, not recruiting

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

United States, Spain, Italy, Taiwan, Belgium, China, Hong Kong, Japan, Germany, Canada, Israel, Russian Federation, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Ukraine, Romania, Australia, Hungary, Portugal
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (CheckMate 451)

Lung Cancer

Australia, China, Romania, Colombia, Ireland, Israel, Japan, Spain, Peru, United States, Brazil, Greece, Singapore, Argentina, Austria, Belgium, Canada, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Mexico, Netherlands, ... and more
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)

Non-Small Cell Lung Cancer

Canada, Belgium, Korea, Republic of, United States, France, Brazil, China, New Zealand, Israel, Spain, Argentina, Serbia, Mexico, Italy, Japan, Turkey, Taiwan, Costa Rica, Thailand, Australia, Germany, Hong Kong, Netherlands, Peru, Poland, Russian Federation and more
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors

United States, Korea, Republic of, Spain, United Kingdom, Brazil, Israel, New Zealand, Netherlands, Canada, Australia, Switzerland, Belgium, Italy, Norway, Poland, Hungary, Kenya, Russian Federation, Germany
Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
Hoffmann-La Roche

Completed

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Italy, Belgium, Israel, Sweden, China, Hong Kong, Australia, Colombia, Romania, Germany, Ireland, Mexico, Korea, Republic of, Taiwan, Turkey, Russian Federation, Czech Republic, Hungary, Netherlands, New Zealand, Peru, Finland, Austria and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Carcinoma, Renal Cell

United States, Australia, Canada, Chile, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Poland, Australia, Russian Federation, Mexico, Brazil, Puerto Rico, U... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Netherlands, Germany
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Canadian Cancer Trials Group
National Health and Medical Research Council, Australia; Dutch Society of Physicians... and other collaborators

Active, not recruiting

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Non-Small Cell Lung Cancer

Canada, United States, France, Spain, Taiwan, China, Australia, Italy, Japan, Singapore, Korea, Republic of, New Zealand, Netherlands, Romania, Bulgaria, Brazil, Hungary, Poland, Ukraine
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Pfizer

Terminated

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Australia, United States, Hungary, Germany, Italy, Korea, Republic of, Spain, Sweden, Mexico, South Africa, Taiwan, Belgium, Canada, China, Cyprus, Czech Republic, France, Greece, Hong Kong, India, Israel, Netherlands, Poland, Portugal, Switzerlan... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Carcinoma, Renal Cell

Spain, United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, United Kingdom

Clinical Trials on Squamous Cell Head and Neck Carcinoma in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations